CTOs on the Move

The Mighty

www.themighty.com

 
The Mighty is a digital health community created to empower and connect people facing health challenges and disabilities. We have over 2.5 million registered users and are adding a new one every 20 seconds. Our stories and videos are viewed and shared more than 90 million times a month. But those are just stats. This experience from a community member is what we`re really after: “How is it that I read an essay on The Mighty and it is the only place in the world where I feel truly understood? Time and time again you speak to me through your ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.themighty.com
  • 210 N Glenoaks Boulevard Suite C
    Burbank, CA USA 91502
  • Phone: 213.379.2407

Executives

Name Title Contact Details
Peter Wang
Chief Technology Officer Profile

Similar Companies

Specialty Media Inc

Specialty Media provides innovative products and services of the highest quality to the academic and industrial biological research community. Our products and services are designed with the needs of the bench researcher in mind. Specialty Media offers

Fisher Center for Alzheimers Research Foundation

Fisher Center for Alzheimers Research Foundation is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iCardiac Technologies

iCardiac Technologies is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Rochester, NY. To find more information about iCardiac Technologies, please visit www.icardiac.com

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.

Copies - FYI

Copies - FYI is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.